Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune
thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as …

Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …

Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved for the treatment of
chronic primary immune thrombocytopenia (ITP) in the United States, Canada and some …

Fostamatinib, a recently approved Syk inhibitor used in adult primary immune
thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However …

Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated
platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk …

Abstract Fostamatinib (Tavalisse®; Tavlesse®) is the first spleen tyrosine kinase (Syk)
inhibitor approved for the treatment of chronic immune thrombocytopenia (ITP) in adult …

Patients with immune thrombocytopenia (ITP) are at increased risk for bleeding and are
paradoxically at increased risk for thrombosis. Many patients with ITP have underlying …

Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of
chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 …

Introduction Primary immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by a low platelet count (< 100× 109/L) with an increased risk of bleeding …

Oral fostamatinib is an orally administered small molecule spleen tyrosine kinase (SYK)
inhibitor approved for the treatment of adults with chronic immune thrombocytopenia (ITP) …